Upcoming REGN earnings date and every past earnings report, with free AI analysis of each 10-K and 10-Q straight from SEC EDGAR filings.
October 26, 2026
Regeneron Pharmaceuticals was scheduled to report on this date in the final Finnhub and Financial Modeling Prep calendar snapshot. Later schedule changes are not reflected.
In Q2 FY2026, Regeneron generated $4.29B in revenue, up 16.7% YoY, driven by strong Dupixent collaboration revenue and EYLEA HD growth, despite persistent…
Regeneron delivered strong Q1 2026 revenue growth of 19.0% YoY to $3.61B, driven by robust product demand, but net income declined 10.1% to $727.2M as R&D…
Regeneron delivered modest FY2025 revenue growth of 1.0% to $14.3B, but operating income fell 10.3% as R&D spending surged 14.0% to $5.85B, while strong…
Regeneron Pharmaceuticals (REGN) is scheduled to report earnings on October 26, 2026, according to Finnhub's earnings calendar. Dates can change until the company officially confirms them.
Regeneron Pharmaceuticals's most recent earnings report was its Q2 FY2026 10-Q, filed with the SEC on July 30, 2026.
EarningsLens publishes free AI analysis of every REGN 10-K and 10-Q filing. The latest covers Q2 FY2026 — open it from the report history on this page.
Like all U.S.-listed public companies, Regeneron Pharmaceuticals reports four times a year: three quarterly 10-Q filings and one annual 10-K filing with the SEC.